Table 1 Baseline characteristics of patients
Characteristic | FOLFOX (n = 1218) | XELOX (n = 973) | p-value1 |
|---|---|---|---|
Males, n (%) | 755 (62.0) | 641 (65.9) | 0.060 |
Age at treatment initiation | 0.859 | ||
Median, (5%-95%) | 61 (43–73) | 62 (43–73) | |
Localization, n (%) | 0.235 | ||
Colon | 717 (58.9) | 596 (61.3) | |
Rectum | 500 (41.1) | 377 (38.7) | |
Not available | 1 (0.1) | 0 (0.0) | |
Thromboembolism, n (%) | 44 (3.6) | 36 (3.7) | 0.923 |
Hypertension, n (%) | 473 (40.4) | 357 (39.0) | 0.511 |
Primarily metastatic, n (%) | 0.021* | ||
M0 | 399 (32.8) | 365 (37.5) | |
M1 | 819 (67.2) | 608 (62.5) | |
Histological type, n (%) | 0.123 | ||
Adenocarcinoma | 1177 (96.6) | 927 (95.3) | |
Other | 22 (1.8) | 18 (1.8) | |
Not available | 19 (1.6) | 28 (2.9) | |
PS, n (%) | <0.001* | ||
0 | 293 (24.1) | 255 (26.2) | |
1 | 303 (24.9) | 130 (13.4) | |
2 | 46 (3.8) | 14 (1.4) | |
3 | 2 (0.1) | 0 (0.0) | |
4 | 1 (0.1) | 0 (0.0) | |
Not available | 573 (47.0) | 574 (59.0) | |
Radiotherapy, n (%) | 0.235 | ||
Adjuvant | 84 (6.9) | 84 (8.6) | |
Neo-adjuvant | 112 (9.2) | 112 (11.5) | |
Other | 18 (1.5) | 14 (1.4) | |
No radiotherapy | 998 (81.9) | 758 (77.9) | |
Not available | 5 (0.4) | 5 (0.5) | |
Neo-adjuvant therapy, n (%) | 99 (8.2) | 89 (9.2) | 0.396 |
Adjuvant therapy, n (%) | 288 (23.7) | 262 (27.1) | 0.068 |